The influence of peptides from the angiotensin family on tyrosine kinase activity and cell viability in a human hormone-dependent prostate cancer line

Endokrynologia Polska

Volumn 60, Issue 5, 2009, Pages 363-369

  Domińska, Kamila ^a   Piastowska, Agnieszka Wanda ^a   Rȩbas, Elzbieta ^a   Lachowicz Ochȩdalska, Agnieszka ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cell viability; Hormone dependent prostate cancer; LNCaP; Losartan; PD123319; PTKs

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; LOSARTAN; PROTEIN TYROSINE KINASE;

ARTICLE; BINDING AFFINITY; CELL STRAIN LNCAP; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN III; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; IMIDAZOLES; LOSARTAN; MALE; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PYRIDINES;

EID: 72449126637     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Kurdi M, De Mello WC, Booz GW. Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components. Int J Biochem Cell Biol. 2005; 37: 1357-1367. (Pubitemid 40502008)
3. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006; 86: 747-803.
4. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab 2007; 18: 208-214. (Pubitemid 46962301)
5. O'Mahony OA, Barker S, Puddefoot JR et al. Synthesis and secretion of angiotensin II by the prostate gland in vitro. Endocrinology 2005; 146: 392-398. (Pubitemid 40051763)
6. O'Mahony OA, Djahanbahkch O, Mahmood T et al. Angiotensin II in human seminal fluid. Hum Reprod 2000; 15: 1345-1349.
7. Chow L, Rezmann L, Catt KJ et al. Role of the renin-angiotensin system in prostate cancer. Mol Cell Endocrinol 2009; 36: 1228-1233.
8. Ino K, Shibata K, Kajiyama H et al. Manipulating the angiotensin system - new approaches to the treatment of solid tumours. Expert Opin Biol Ther 2006; 6: 243-255. (Pubitemid 43344744)
9. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005; 16: 293-299.
10. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20: 953-970.
11. Haendler J, Berk BC. Angiotensin II mediated signal transduction -important role of tyrosine kinases Reg Peptides 2000; 95: 1-7.
12. Uemura H, Ishiguro H, Nakaigawa N et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003; 2: 1139-1147.
13. AbdAlla S, Lother H, Abdel-tawab AM et al. The Angiotensin II AT2 Receptor Is an AT1 Receptor Antagonist. J. Biol Chem 2001; 276: 39721-39726. (Pubitemid 37391377)
14. Dinh DT, Frauman AG, Johnston CI et al. Angiotensin receptors: distribution, signalling and function. Clin Sci 2001; 100: 481-492. (Pubitemid 32434113)
15. Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens 2005; 18: 134S-141S.
16. Haulica I, Bild W, Serban DN. Angiotensin peptides and their pleiotropic actions. J Renin Angiotensin Aldosterone Syst 2005; 6: 121-131. (Pubitemid 43263350)
17. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines. Urol 2005; 173: 342-359.
18. Dinh DT, Frauman AG, Somers GR et al. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol 2002; 196: 213-219.
19. Dinh DT, Frauman AG, Sourial M et al. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology 2001; 142: 1349-1356. (Pubitemid 32202848)
20. Ochȩdalska AL, Rȩbas E, Kunert-Radek J et al. Angiotensins II and IV stimulate the activity of tyrosine kinases in estrogen-induced rat pituitary tumors. Biochem Biophys Res Commun 2002; 297: 931-933 (Pubitemid 35230340)
21. Paul MK, Mukhopadhyay AK. Tyrosine kinase - Role and significance in Cancer. Int J Med Sci. 2004; 1: 101-115.
22. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Therap. 2004; 3: 349-380.
23. Rȩbas E, Lachowicz-Ochȩdalska A, Pawlikowski M. Angiotensin IV stimulates the activity of tyrosine kinases in rat anterior pituitary gland acting via AT1-like receptors? J Physiol Pharmacol 2004; 55: 107-111.
24. Gavi S, Shumay E, Wang HY et al. G-protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation. Trends Endocrinol Metab 2006; 17: 48-54. (Pubitemid 43306727)
25. Ławnicka H, Potocka AM, Juzala A et al. Angiotensin II and its fragments (angiotensins III and IV) decrease the growth of DU-145 prostate cancer in vitro. Med Sci Monit 2004; 10: 410-413
26. Vauquelin G, Michotte Y, Smolders I et al. Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. J Renin Angiotensin Aldosterone Syst. 2002; 3: 195-204.
27. Dinh DT, Frauman AG, Casley DJ et al. Angiotensin AT(4) receptors in the normal human prostate and benign prostatic hyperplasia. Mol Cell Endocrinol 2001; 184: 187-192.
28. Pawlikowski M, Meleń-Mucha G, Mucha S. The involvement of angiotensins in the control of prostatic epithelial cell proliferation in the rat. Folia Histochem Cytobiol 2001; 39: 341-343. (Pubitemid 33026350)
29. Chow L, Rezmann L, Imamura K et al. Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines. Prostate 2008; 68: 651-660. (Pubitemid 351614643)
30. Wennemuth G, Aumüller G. Angiotensin H-mediated calcium signals and mitogenesis in human prostate stromal cell line hPCPs. Br J Pharmacol 2005; 144: 3-10. (Pubitemid 40188543)
31. Teranishi J, Ishiguro H, Hoshino K et al. Evaluation of role of angiotensin III and aminopeptidases in prostate cancer cells. Prostate 2008; 68: 1666-1673.
32. Menon J, Soto-Pantoja DR, Callahan MF et al. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res. 2007; 67: 2809-2815.